DrugPatentWatch Database Preview
Lannett Company Profile
What is the competitive landscape for LANNETT, and what generic alternatives to LANNETT drugs are available?
LANNETT has one hundred and ninety-five approved drugs.
There is one US patent protecting LANNETT drugs.
There are fifteen patent family members on LANNETT drugs in twelve countries and one hundred and sixty supplementary protection certificates in thirteen countries.
Summary for Lannett
| International Patents: | 15 |
| US Patents: | 1 |
| Tradenames: | 143 |
| Ingredients: | 133 |
| NDAs: | 195 |
| Patent Litigation for Lannett: | See patent lawsuits for Lannett |
| PTAB Cases with Lannett as petitioner: | See PTAB cases with Lannett as petitioner |
Drugs and US Patents for Lannett
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett Co Inc | PAROXETINE HYDROCHLORIDE | paroxetine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204744-002 | Jun 10, 2016 | AB | RX | No | No | See Pricing | See Pricing | ||||
| Lannett Co Inc | METHYLPHENIDATE HYDROCHLORIDE | methylphenidate hydrochloride | TABLET;ORAL | 086429-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | See Pricing | See Pricing | |||||
| Lannett Co Inc | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-005 | Feb 19, 2006 | AB2 | RX | Yes | No | See Pricing | See Pricing | ||||
| Lannett Co Inc | CODEINE SULFATE | codeine sulfate | TABLET;ORAL | 203046-001 | Jun 13, 2014 | AB | RX | No | No | See Pricing | See Pricing | ||||
| Lannett | AMINOPHYLLINE | aminophylline | TABLET;ORAL | 084588-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | See Pricing | See Pricing | |||||
| Lannett Co Inc | AMANTADINE HYDROCHLORIDE | amantadine hydrochloride | SYRUP;ORAL | 076352-001 | Sep 10, 2004 | DISCN | No | No | See Pricing | See Pricing | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lannett
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lannett Co Inc | MYKROX | metolazone | TABLET;ORAL | 019532-001 | Oct 30, 1987 | 4,517,179 | See Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LANNETT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Extended-release Capsules | 40 mg | ➤ Subscribe | 2007-03-15 |
| ➤ Subscribe | Extended-release Capsules | 10 mg, 20 mg and 30 mg | ➤ Subscribe | 2005-05-13 |
International Patents for Lannett Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2426883 | See Pricing |
| European Patent Office | 2286815 | See Pricing |
| Spain | 2618603 | See Pricing |
| Poland | 203828 | See Pricing |
| Norway | 20031843 | See Pricing |
| European Patent Office | 1328251 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lannett Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0770388 | PA2009004 | Lithuania | See Pricing | PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103 |
| 0206283 | SPC/GB97/085 | United Kingdom | See Pricing | PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606 |
| 1602370 | SPC/GB09/024 | United Kingdom | See Pricing | PRODUCT NAME: COMBINATION COMPRISING ALISKIREN, AS THE FREE BASE OR AS A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5893501 20081028; CH 5893502 20081028; CH 5893503 20081028; CH 5893504 20081028; UK EU/1/08/491/006 20090116; UK EU/1/08/491/002 20090116; UK EU/1/08/491/003 20090116; UK EU/1/08/491/004 20090116; UK EU/1/08/491/005 20090116; UK EU/1/08/491/007 20090116; UK EU/1/08/491/080 20090116; UK EU/1/08/491/074 20090116; UK EU/1/08/491/075 20090116; UK EU/1/08/491/076 20090116; UK EU/1/08/491/077 20090116; UK EU/1/08/491/078 20090116; UK EU/1/08/491/079 20090116; UK EU/1/08/491/068 20090116; UK EU/1/08/4 |
| 0509752 | SPC/GB99/043 | United Kingdom | See Pricing | PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804 |
| 0136011 | C00136011/03 | Switzerland | See Pricing | PRODUCT NMAE: ESTRADIOL UND MEDROXYPROGESTERONACETAT; REGISTRATION NO/DATE: IKS 55288 20000417 |
| 0503785 | 91330 | Luxembourg | See Pricing | CERTIFICATE TITLE: UNE COMBINAISON D'OLMESARTAN MEDOXOMIL, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET D'HYDROCHLOROTHIAZIDE (OLMETEC PLUS) |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
